Status:
COMPLETED
Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults
Lead Sponsor:
Albert Einstein College of Medicine
Collaborating Sponsors:
Abbott
University of Alabama at Birmingham
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
HIV infected patients, aged \</= 35 years and aged \>/= 55 years, who are regularly taking either efavirenz (EFV) or lopinavir/ritonavir (Lop/r) as part of their antiretroviral regimen are being asked...
Detailed Description
HIV infected patients, aged \</= 35 years and aged \>/= 55 years, who are regularly taking either efavirenz or lopinavir/ritonavir as part of their antiretroviral regimen are being asked to spend 12 h...
Eligibility Criteria
Inclusion
- HIV+
- Taking lopinavir/ritonavir or efavirenz
- Age \</= 35 years or \>/= 55 years
Exclusion
- Concurrent therapy with drugs that alter lopinavir/ritonavir levels.
- Other renal or kidney disease.
- Chronic hepatitis B or C
Key Trial Info
Start Date :
August 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00179335
Start Date
August 1 2003
End Date
September 1 2006
Last Update
April 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jacobi Medical Center ACS Clinic
The Bronx, New York, United States, 10461